Neurocrine Biosciences | NBIX - Ebitda





Ebitda Cambiamento Data
AbbVie USD 3.69B 1.68B 2026-03
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
ALKERMES USD 139.22M 58.96M 2026-06
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amgen USD 5.14B 775M 2025-12
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Exelixis USD 258.29M 15.43M 2026-03
Gilead Sciences USD 3.02B 1.01B 2025-12
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Prothena USD 25.98M 65.51M 2026-03
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Repligen USD 43.77M 3.76M 2026-06
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Teva Pharmaceutical Industries USD 474M 581M 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03